AbbVie (NYSE: ABBV) announced safety and preliminary efficacy data from a Phase 1 study of ABT-414 – an investigational antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Morgan Stanley Downgrades Abbvie (ABBV) to EqualweightJune 8, 2016 6:34 AM AbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLLJune 6, 2016 9:03 AM Cowen Cuts Abbvie (ABBV) to Market Perform; Analyst Calls Rova-T Data at ASCO 'Underwhelming'June 6, 2016 7:36 AM AbbVie (ABBV) Issues Positive Update on Rova-T as r/r SCLC TreatmentJune 6, 2016 6:26 AM AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual MeetinJune 5, 2016 9:00 AM